Bristol-Myers Squibb Company (BMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has a cash flow conversion efficiency ratio of 0.055x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.10 Billion) by net assets ($20.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Bristol-Myers Squibb Company fund operations to measure how many days the company can operate on defensive assets alone.
Bristol-Myers Squibb Company - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Bristol-Myers Squibb Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bristol-Myers Squibb Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bristol-Myers Squibb Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Altria Group
NYSE:MO
|
-0.948x |
|
PDD Holdings Inc.
NASDAQ:PDD
|
0.110x |
|
Stryker Corporation
NYSE:SYK
|
0.096x |
|
Newmont Goldcorp Corp
NYSE:NEM
|
0.069x |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
N/A |
|
GlaxoSmithKline PLC ADR
NYSE:GSK
|
0.050x |
|
Starbucks Corporation
NASDAQ:SBUX
|
-0.043x |
|
HDFC Bank Limited
F:HDFA
|
N/A |
Annual Cash Flow Conversion Efficiency for Bristol-Myers Squibb Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Bristol-Myers Squibb Company from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see BMY market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.51 Billion | $14.16 Billion | 0.765x | -17.47% |
| 2024-12-31 | $16.39 Billion | $15.19 Billion | 0.927x | +97.18% |
| 2023-12-31 | $29.48 Billion | $13.86 Billion | 0.470x | +11.95% |
| 2022-12-31 | $31.12 Billion | $13.07 Billion | 0.420x | -6.72% |
| 2021-12-31 | $36.01 Billion | $16.21 Billion | 0.450x | +21.35% |
| 2020-12-31 | $37.88 Billion | $14.05 Billion | 0.371x | +137.72% |
| 2019-12-31 | $51.70 Billion | $8.07 Billion | 0.156x | -68.80% |
| 2018-12-31 | $14.13 Billion | $7.07 Billion | 0.500x | +12.33% |
| 2017-12-31 | $11.85 Billion | $5.28 Billion | 0.445x | +138.02% |
| 2016-12-31 | $16.35 Billion | $3.06 Billion | 0.187x | +28.18% |
| 2015-12-31 | $14.42 Billion | $2.10 Billion | 0.146x | -30.54% |
| 2014-12-31 | $14.98 Billion | $3.15 Billion | 0.210x | -9.70% |
| 2013-12-31 | $15.24 Billion | $3.54 Billion | 0.233x | -54.28% |
| 2012-12-31 | $13.64 Billion | $6.94 Billion | 0.509x | +66.85% |
| 2011-12-31 | $15.87 Billion | $4.84 Billion | 0.305x | +6.22% |
| 2010-12-31 | $15.64 Billion | $4.49 Billion | 0.287x | +4.45% |
| 2009-12-31 | $14.79 Billion | $4.07 Billion | 0.275x | -9.46% |
| 2008-12-31 | $12.21 Billion | $3.71 Billion | 0.304x | +1.72% |
| 2007-12-31 | $10.56 Billion | $3.15 Billion | 0.299x | +43.18% |
| 2006-12-31 | $9.99 Billion | $2.08 Billion | 0.208x | +27.27% |
| 2005-12-31 | $11.21 Billion | $1.84 Billion | 0.164x | -47.38% |
| 2004-12-31 | $10.20 Billion | $3.18 Billion | 0.311x | -13.25% |
| 2003-12-31 | $9.79 Billion | $3.51 Billion | 0.359x | +232.52% |
| 2002-12-31 | $8.76 Billion | $945.00 Million | 0.108x | -78.55% |
| 2001-12-31 | $10.74 Billion | $5.40 Billion | 0.503x | -0.71% |
| 2000-12-31 | $9.18 Billion | $4.65 Billion | 0.507x | +3.71% |
| 1999-12-31 | $8.64 Billion | $4.22 Billion | 0.489x | -2.12% |
| 1998-12-31 | $7.58 Billion | $3.78 Billion | 0.499x | +45.55% |
| 1997-12-31 | $7.22 Billion | $2.48 Billion | 0.343x | -14.68% |
| 1996-12-31 | $6.57 Billion | $2.64 Billion | 0.402x | -6.35% |
| 1995-12-31 | $5.82 Billion | $2.50 Billion | 0.429x | +6.40% |
| 1994-12-31 | $5.70 Billion | $2.30 Billion | 0.403x | -7.12% |
| 1993-12-31 | $5.94 Billion | $2.58 Billion | 0.434x | +28.93% |
| 1992-12-31 | $6.02 Billion | $2.03 Billion | 0.337x | +6.39% |
| 1991-12-31 | $5.79 Billion | $1.83 Billion | 0.317x | -2.08% |
| 1990-12-31 | $5.42 Billion | $1.75 Billion | 0.323x | +38.15% |
| 1989-12-31 | $5.08 Billion | $1.19 Billion | 0.234x | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more